<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13653673
    </Internal_Number>
    <TrialID>RBR-6xtvg5w
    </TrialID>
    <Last_Refreshed_on>23 January 2024
    </Last_Refreshed_on>
    <Public_title>Effects of transcutaneous auricular vagus nerve stimulation in individuals with Parkinson&amp;apos;s disease - a double-blind randomized controlled clinical trial
    </Public_title>
    <Scientific_title>Effects of non-invasive transcutaneous auricular vagus nerve electrical stimulation in individuals with Parkinson&amp;apos;s disease - A double-blind randomized controlled clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Universidade Federal de São Carlos
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20240108
    </Date_registration3>
    <Date_registration>08/01/2024
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>https://ensaiosclinicos.gov.br/rg/RBR-6xtvg5w
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40Y
    </Inclusion_agemin>
    <Inclusion_agemax>80Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>23/10/2023
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Jose;Anna
    </Contact_Firstname>
    <Contact_Lastname>Prati;Lepesteur Gianlorenço
    </Contact_Lastname>
    <Contact_Address>Rodovia Washington Luiz, km 235, SP-310, Bairro Monjolinho;Rodovia Washington Luiz, km 235, SP-310, Bairro Monjolinho
    </Contact_Address>
    <Contact_Email>jmprati@estudante.ufscar.br;gianlorenco@ufscar.br
    </Contact_Email>
    <Contact_Tel>+55(16)3351-8628;+55(16)3351-8628
    </Contact_Tel>
    <Contact_Affiliation>Universidade Federal de São Carlos;Universidade Federal de São Carlos
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Individuals of both sexes; aged between 40-80 years, with a diagnosis confirmed by a neurologist of Parkinson&amp;apos;s disease present in stages 1 to 3 of the Hoehn and Yahr scale; who have motor and cognitive complaints related to the Unified Parkinson&amp;apos;s Disease Rating Scale (UPDRS) and who have been on stable Parkinson Disease medication for at least 30 days
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Individuals with characteristics of other types of parkinsonism; having other health conditions such as musculoskeletal problems, decompensated respiratory or cardiovascular problems, uncontrolled diabetes, uncontrolled systemic arterial hypertension, psychiatric conditions such as dementia diagnosed by a psychiatrist, contraindications for the intervention (implanted cardiac or cranial electronic medical devices, cochlear implant, pacemaker) or conditions in which the principal investigator assesses as not indicated for participation in the study
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;apos;s disease;C10.228.140.079.862
    </Condition>
    <Intervention>Participants will initially undergo a clinical screening to collect demographic and health data. Subsequently, eligible participants will be randomized into  active transcutaneous auricular vagus nerve stimulation group and sham transcutaneous auricular vagus nerve stimulation group. The groups will consist of 13 participants, totaling 26 participants in the study. The evaluation will take place over two days. On the first day, questionnaires will be applied to assess disease staging (Hoehn and Yahr Scale); general impairment and disease progression (UPDRS); quality of life (PDQ-39); cognitive function (Addenbrooke&amp;apos;s Cognitive Examination); and involuntary movements (Abnormal Involuntary Movements Scale - MSD Manual). Also on the first day, participants will be assessed for heart rate variability and upper limb tremor using an accelerometer. On the second day, functional tests will be carried out to assess gait (Time up and Go - TUG and dual-task TUG - TUG-DT); functional mobility (Sit and stand test five times); fine motor function and manual dexterity (Nine pin test); grip strength (hand dynamometer); and isokinetic assessment of the bilateral knee and elbow using an isokinetic dynamometer (Biodex 4). After the two-day evaluation, the intervention protocol will begin. The participants will be randomized between the groups by an independent researcher who will numerate the transcutaneous auricular vagus nerve stimulation equipment in different numbers (1 or 2) according to the programming of the equipment (active stimulation or sham stimulation). Only this independent researcher knows which equipment will be active stimulation or sham stimulation. This researcher will have no contact with the research participants.The intervention protocol consists of 12 sessions 
    </Intervention>
    <Primary_outcome>Evaluate the overall function of individuals with Parkinson&amp;apos;s disease throught the Unified Parkinson Disease Rating Scale (UPDRS). The result will be assessed by comparing the score in the pre- and post-intervention evaluation. It is expected that there will be no significant difference in most of the items on the assessment tool, with the exception of the motor section
    </Primary_outcome>
    <Secondary_outcome>Evaluate the cognition throught the Addenbrooke&amp;apos;s Cognitive Examination. The result will be evaluated by comparing the score in the pre- and post-intervention evaluation. It is expected that there will be no significant difference in the cognitive capacity of the participants;Evaluate the quality of life through the Parkinson&amp;apos;s Disease Questionnarie (PDQ-39). We will analyze the participants&amp;apos; scores on this evaluation instrument pre- and post-intervention. The result will be evaluated by comparing the participants&amp;apos; scores in the pre- and post-intervention evaluation. It is expected that there will be a significant difference in the participants&amp;apos; quality of life as a result of improved motor functions, as previous studies have shown;Evaluate the grip strenght through the manual dynamometer. The outcome will be assessed by comparing the participants&amp;apos; grip strength scores at pre- and post-intervention. It is expected that there will be no significant difference in the participants&amp;apos; grip strength;Evaluate the heart rate variability through the Polar watch. The results will be evaluated by comparing the heart rate variability measurements of the participants in the pre- and post-intervention evaluation. The studies show that the effect of transcutaneous auricular stimulation of the vagus nerve on heart rate variability is inconclusive. Therefore, it is expected that there will be no significant difference in the heart rate variability of the participants;Evaluate the gait speed through the Timed Up and Go test (TUG). We will analyze the participants&amp;apos; gait speed using this test in the pre- and post-intervention. The result will be evaluated by comparing the participants&amp;apos; gait speed measurements in the pre- and post-intervention evaluation. Recent studies have shown that transcutaneous auricular stimulation of the vagus nerve improves different gait variables such as step length, stride velocity, stride length and step length variability. Therefore, transcutaneous auricular vagus nerve stimulation is expected to improve the gait of the participants;Evaluate the upper and lower limbs strenght through the isokinetic dynamometer (Biodex 4). The results will be evaluated by comparing the strength and peak torque measurements of the upper and lower limbs of the participants in the pre- and post-intervention evaluation. It is expected that there will be no significant difference in the strength and peak torque of the participants;Evaluate the fine motor function and manual dexterity through the Nine Hole Peg Test. The result will be evaluated by comparing the participants&amp;apos; fine motor function and manual dexterity measures in the pre- and post-intervention evaluation. It is expected that there will be an improvement in the fine motor function and manual dexterity of the participants
    </Secondary_outcome>
    <Source_Support>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES
    </Source_Support>
    <Secondary_Sponsor>Universidade Federal de São Carlos
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>23/06/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>cephumanos@ufscar.br
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comitê de Ética em Pesquisa  da Universidade Federal de São Carlos 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+55(16)3351-9685
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>cephumanos@ufscar.br
    </Ethics_review_contact_email>
    <results_date_completed>31/12/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13653489
    </Internal_Number>
    <TrialID>JPRN-UMIN000052862
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>The effects of transcutaneous auricular vagus nerve stimulation on postural instability in patients with Parkinson&amp;#39;s disease
    </Public_title>
    <Scientific_title>The effects of transcutaneous auricular vagus nerve stimulation on postural instability in patients with Parkinson&amp;#39;s disease - Transcutaneous auricular vagus nerve stimulation for postural instability in Parkinson&amp;#39;s disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Kio University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231122
    </Date_registration3>
    <Date_registration>22/11/2023
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060327
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>90years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2023/12/01
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Cross-over Randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Yohei
    </Contact_Firstname>
    <Contact_Lastname>Okada
    </Contact_Lastname>
    <Contact_Address>4-2-2 umami-naka koryo-cho, kitakatsuragi-gun, Nara, 635-0832 JAPAN
    </Contact_Address>
    <Contact_Email>y.okada@kio.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-745-54-1601
    </Contact_Tel>
    <Contact_Affiliation>Kio University Graduate School of Health Sciences
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1)Coexistence of Neurological Disorders Other Than Parkinson&amp;#39;s Disease  2)Deep Brain Stimulation Therapy  3)Metallic Substances in the Body  4)Decline in Cognitive Function  5)History of Cardiovascular Disease  6)Orthostatic Hypotension  7)Vagus Nerve Reflex
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Transcutaneous auricular vagus nerve stimulation&lt;br&gt;Sham stimulation
    </Intervention>
    <Primary_outcome>Outcomes on postural instability during standing and walking
    </Primary_outcome>
    <Secondary_outcome>Motor symptoms, non-motor symptoms
    </Secondary_outcome>
    <Source_Support>Grants-in-Aid for Scientific Research
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/12/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>y.okada@kio.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethics Review Committee of Kio University
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-745-54-1601
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>y.okada@kio.ac.jp
    </Ethics_review_contact_email>
    <results_date_completed>31/03/2027
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13212067
    </Internal_Number>
    <TrialID>NCT05950347
    </TrialID>
    <Last_Refreshed_on>7 August 2023
    </Last_Refreshed_on>
    <Public_title>The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Anxiety in PD
    </Public_title>
    <Scientific_title>The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Anxiety in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The First Affiliated Hospital with Nanjing Medical University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230710
    </Date_registration3>
    <Date_registration>10/07/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05950347
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2023
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Zhang Kezhong
    </Contact_Lastname>
    <Contact_Email>kezhong_zhang1969@126.com
    </Contact_Email>
    <Contact_Tel>13770840575
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (1) diagnosed with idiopathic PD according to the Movement Disorder Society Clinical&#x0D;&lt;br&gt;             Diagnostic Criteria for PD;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (2) meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition&#x0D;&lt;br&gt;             (DSM-5) criteria for anxiety and Hamilton Anxiety Scale (HAMA) score = 12;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (3) stable pharmacotherapy for PD at least one month prior to the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (4) 40-80 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (5) willing to sign written informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (1) with cognitive impairment, according to Montreal Cognitive Assessment (MOCA) &lt; 23;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (2) took antianxiety drugs;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (3) with taVNS contraindications;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (4) received VNS treatment during the past month;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  (5) with concomitant severe neurologic, renal, cardiovascular, or hepatic disease.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Active Transcutaneous auricular vagus nerve stimulation;Device: Sham Transcutaneous auricular vagus nerve stimulation
    </Intervention>
    <Primary_outcome>change of Hamilton Anxiety Scale Score
    </Primary_outcome>
    <Secondary_outcome>change of HbO2 in the prefrontal cortex;change of Uni?ed Parkinson's Disease Rating Scale Score section III;change of Uni?ed Parkinson's Disease Rating Scale Score section I
    </Secondary_outcome>
    <Secondary_ID>2023-07
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13501936
    </Internal_Number>
    <TrialID>NCT05967598
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect of taVNS of Brainstem Activation in Early and Late Parkinson's Disease Patients - an fMRI Study
    </Public_title>
    <Scientific_title>Effect of Transcutaneous Auricular Vagl Nerve Electrostimulation of Brainstem Structures in Early and Late Parkinson's Disease Patients - an fMRI Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Ljubljana
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230405
    </Date_registration3>
    <Date_registration>05/04/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05967598
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 15, 2023
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Slovenia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Andrej Vovk, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medical Faculty, University of Ljubljana
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of Parkinson's disease according to the UK PD Society Brain Bank criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to walk independently for at least 2 minutes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cognitive impairment that might prevent cooperation during tests&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  stable antiparkinsonian medications during the previous 1 month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medication resistant rest tremor or dyskinesias&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  implanted medical devices or metal implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  claustrophobia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  fixed or severe kyphosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any conditions that would prevent our patients from lying still for 1 hour in a supine&#x0D;&lt;br&gt;             position (i.e. muscle pain, degenerative joint diseases…).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Neurologic Disorder
    </Condition>
    <Intervention>Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz;Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz;Device: Sham cyma conchae stimulation
    </Intervention>
    <Primary_outcome>Comparison of Brainstem activation pattern on fMRI (ROI analysis) during taVNS compared to xVNS;Comparison of Functional connectivity pattern on fMRI (block design) of nucleus tractus solitarii and the rest of the nervous system during taVNS compared to xVNS;Comparison of Functional connectivity pattern on fMRI (block design) of locus coeruleus (LC) and the rest of the nervous system during taVNS compared to xVNS
    </Primary_outcome>
    <Secondary_outcome>Comparison of Brainstem activation pattern on fMRI (ROI analysis) during taVNS25 compared to taVNS100;Comparison of Functional connectivity pattern on fMRI (block design) of nucleus tractus solitarii and the rest of the nervous system during taVNS25 compared to taVNS100;Comparison of Functional connectivity pattern on fMRI (block design) of locus coeruleus (LC) and the rest of the nervous system during taVNS100 compared to taVNS25
    </Secondary_outcome>
    <Secondary_ID>012052/2020-2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Medical Centre Ljubljana
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>12974257
    </Internal_Number>
    <TrialID>NCT05806736
    </TrialID>
    <Last_Refreshed_on>17 April 2023
    </Last_Refreshed_on>
    <Public_title>Curative Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation on Non-motor Symptoms of PD
    </Public_title>
    <Scientific_title>Study on the Efficacy and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in the Treatment of Non-motor Symptoms of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The First Affiliated Hospital with Nanjing Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230227
    </Date_registration3>
    <Date_registration>27/02/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05806736
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2022
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kezhong Zhang;Kezhong Zhang;Kezhong Zhang
    </Contact_Lastname>
    <Contact_Email>;kezhong_zhang1969@126.com;kezhong_zhang1969@126.com
    </Contact_Email>
    <Contact_Tel>;13770840575;13770840575
    </Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital with Nanjing Medical University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's disease (PD), as diagnosed by a neurologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PDSS score&lt;82 (or a subscore&lt;5).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 40 and 80 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini-Mental State Examination score &gt;24.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-handed patient.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically diagnosed as other Parkinson's syndrome.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive impairment (MMSE&lt;24), severe anxiety and depression, epilepsy history,&#x0D;&lt;br&gt;             severe diabetes, organic brain stem injury (such as stroke, tumor, demyelinating&#x0D;&lt;br&gt;             disease, etc.).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Taking anticholinergic drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Taking antipsychotic drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  There are contraindications to taVNS stimulation, such as implantation of a cardiac&#x0D;&lt;br&gt;             pacemaker after DBS operation, patients with local infection or loss of an ear, or&#x0D;&lt;br&gt;             metal implants at the stimulation site.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  There is uncontrolled hypertension, coronary heart disease, or recent acute myocardial&#x0D;&lt;br&gt;             infarction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who cannot complete follow-up.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcutaneous auricular vagus nerve stimulation (real stimulation);Device: Transcutaneous auricular vagus nerve stimulation (sham stimulation)
    </Intervention>
    <Primary_outcome>Changes of non-motor symptom scale;Changes of sleep quality scale;Changes of Rapid-eye-movement Sleep Behavior Disorder scale
    </Primary_outcome>
    <Secondary_outcome>The motor part of the Unified Parkinson's Disease Rating Scale;Serological indicators;Resting motor threshold (RMT);Cortical silent period (CSP);Short interval intracortical inhibition (SICI);Intracortical facilitation (ICF);Changes in ?HbO2 concentration in the brain cortex;Changes in the cognitive changes;Change of anxiety level of patients;Changes in depression level of patients;Changes in sleep quality, sleep efficiency and other sleep indicators of patients;Changes in patients' fatigue;Changes in patients' anxiety level;Changes in the cognitive degree;Plasma indicators;Changes in sleep quality, sleep efficiency of patients
    </Secondary_outcome>
    <Secondary_ID>2022-SR-519
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Natural Science Foundation of China
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13058640
    </Internal_Number>
    <TrialID>ChiCTR2300067988
    </TrialID>
    <Last_Refreshed_on>15 May 2023
    </Last_Refreshed_on>
    <Public_title>Efficacy of transcutaneous ear vagus nerve stimulation on non-motor symptoms of Parkinson's patients
    </Public_title>
    <Scientific_title>Efficacy of transcutaneous ear vagus nerve stimulation on non-motor symptoms of Parkinson's patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Zhejiang Provincial People's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230202
    </Date_registration3>
    <Date_registration>2023-02-02
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>https://www.chictr.org.cn/showproj.html?proj=189026
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>75
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2023-02-02
    </Date_enrollement>
    <Target_size>Experimental Group:30;Control Group:30;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>1
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Zhenhua Jin
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>158 Shangtang Road, Gongshu District, Hangzhou, Zhejiang, China
    </Contact_Address>
    <Contact_Email>ketteronce@qq.com
    </Contact_Email>
    <Contact_Tel>+86 180 6794 0680
    </Contact_Tel>
    <Contact_Affiliation>Zhejiang Provincial People's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Meet the diagnostic criteria of the Chinese Parkinson's disease diagnostic criteria (2016 edition);&lt;br&gt;2. Parkinson's stage is greater than or equal to stage 2 to stage 5; &lt;br&gt;3. Disease duration &gt;=5 years; &lt;br&gt;4. Volunteer to participate in this study and sign the research informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. People with metal implants in the body, such as those with a pacemaker in the heart; &lt;br&gt;2. People with severe disturbance of consciousness or unable to cooperate with follow-up treatment evaluation; &lt;br&gt;3. People with a history of epilepsy in the past, or people with epilepsy after the onset; &lt;br&gt;4. People with severe heart disease. , liver, kidney and other organ dysfunction; &lt;br&gt;5. progressive disease and significantly increased intracranial pressure.
    </Exclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Experimental Group:Transcutaneous ear vagus nerve stimulation;Control Group:sham 	Transcutaneous ear vagus nerve stimulation ;
    </Intervention>
    <Primary_outcome>NMSS, non-motor symptom scale;
    </Primary_outcome>
    <Secondary_outcome>UPDRS, unified Parkinson’s Disease rating scale;MMSE, Minimal Mental State  Examination;QOL,Quality  of Living;
    </Secondary_outcome>
    <Source_Support>self-financing
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/12/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Yuqing Feng
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13509803
    </Internal_Number>
    <TrialID>NCT05683925
    </TrialID>
    <Last_Refreshed_on>30 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Characteristics in Parkinson's Disease
    </Public_title>
    <Scientific_title>Effect of Transcutaneous Auricular Vagus Nerve Stimulation at 25Hz and 100Hz on Levodopa Responsive and Non-responsive Gait Characteristics in Parkinson's Disease- a Motion Sensor Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Medical Centre Ljubljana
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221219
    </Date_registration3>
    <Date_registration>19/12/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05683925
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2022
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Slovenia
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Maja Kojovic, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Medical Centre Ljubljana
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  HYstage &gt;2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  L-dopa unresponsive gait characteristics present, preferably with history of freezings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unable to walk for 50m&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unable to follow simple commands due to hearing loss/cognitive impairment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Gait Disorders, Neurologic
    </Condition>
    <Intervention>Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz;Device: Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz;Device: Noninvasive transcutaneous earlobe stimulation at 25Hz
    </Intervention>
    <Primary_outcome>Arm Swing Velocity;Arm Range of Motion;Stride Length;Gait Speed;Arm Range of Motion Asymmetry;Anticipatory Postural Adjustment (APA) duration;APA First step Duration;APA First Step range of motion
    </Primary_outcome>
    <Secondary_ID>012052/2020/2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>12622357
    </Internal_Number>
    <TrialID>NCT05561348
    </TrialID>
    <Last_Refreshed_on>24 October 2022
    </Last_Refreshed_on>
    <Public_title>The Effect and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Impairments in PD
    </Public_title>
    <Scientific_title>Study on the Therapeutic Effect and Brain Mechanism of Transcutaneous Vagal Nerve Stimulation on Gait Impairments in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The First Affiliated Hospital with Nanjing Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220922
    </Date_registration3>
    <Date_registration>22/09/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05561348
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2022
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Zhang Kezhong;Zhang Kezhong;Kezhong Zhang
    </Contact_Lastname>
    <Contact_Email>;kezhong_zhang1969@126.com;kezhong_zhang1969@126.com
    </Contact_Email>
    <Contact_Tel>;13770840575;13770840575
    </Contact_Tel>
    <Contact_Affiliation>The First Affiliated Hospital with Nanjing Medical University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Idiopathic Parkinson's disease (PD), as diagnosed by a neurologist.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Hoehn and Yahr stage = 2 during ON medication state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age between 40 and 80 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Mini-Mental State Examination score &gt;24.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Ability to walk at least 60s independently.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Stable medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with significant visual impairment or coexisting local or systemic diseases&#x0D;&lt;br&gt;             (e.g. osteoarthritis or other neurological conditions) likely to affect gait were&#x0D;&lt;br&gt;             excluded from our study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients who underwent deep brain stimulation surgery or those with an implanted&#x0D;&lt;br&gt;             cardiac pacemaker were also excluded&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with known or suspected cardiovas-cular disease, uncontrolled hypertension or&#x0D;&lt;br&gt;             recent myocardial infarction were also excluded from the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcutaneous auricular vagus nerve stimulation
    </Intervention>
    <Primary_outcome>Change from Baseline Velocity at one day post intervention;Change from Baseline Step length at one day post intervention;Change from Baseline arm ROM maximum at one day post intervention;Change from Baseline turning average duration velocity at one day post intervention;Change from Baseline gait cycle at one day post intervention;Change from Baseline Unified Parkinson's Disease Rating Scale-III at one day post intervention;Changes in Tinetti Gait scores at one day post intervention;Changes in Tinetti Balance scores at one day post intervention
    </Primary_outcome>
    <Secondary_outcome>Changes in ?HbO2 concentration in the brain cortex
    </Secondary_outcome>
    <Secondary_ID>2022-SR-535
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:23:44</Export_date>
    <Internal_Number>13393191
    </Internal_Number>
    <TrialID>ISRCTN19394828
    </TrialID>
    <Last_Refreshed_on>9 October 2023
    </Last_Refreshed_on>
    <Public_title>Improving neural control of gait in Parkinson's disease
    </Public_title>
    <Scientific_title>Adjunctive vagus nerve stimulation for improving neural control of gait in Parkinson’s disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Newcastle upon Tyne Hospitals NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210823
    </Date_registration3>
    <Date_registration>23/08/2021
    </Date_registration>
    <Source_Register>ISRCTN
    </Source_Register>
    <web_address>https://www.isrctn.com/ISRCTN19394828
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>15/11/2021
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized; Interventional; Design type: Treatment, Device (Treatment)
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>United Kingdom;England
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                1. Diagnosis of Parkinson’s disease, as defined by the UK Brain Bank Criteria&lt;br&gt;                2. Hoehn and Yahr stage I – III&lt;br&gt;                3. Stable medication for preceding one month and anticipated over next 3 months&lt;br&gt;                4. Able to walk independently without aid for a minimum of 2 minutes without rest&lt;br&gt;                5. Able to provide informed consent&lt;br&gt;                6. Aged &lt;75 years&lt;br&gt;            
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                1. Parkinson’s disease dementia or significant cognitive impairment (Montreal Cognitive Assessment (MoCA) score &lt;21)&lt;br&gt;                2. History of stroke, traumatic brain injury, intracranial aneurysm, intracranial haemorrhage, brain tumour or atypical parkinsonian disorder&lt;br&gt;                3. Unstable medical condition in the last 6 months, or planned surgeries that may involve implants within the next 6 months&lt;br&gt;                4. Prescribed centrally acting anticholinergics (e.g., amitriptyline) and cholinesterase inhibitors&lt;br&gt;                5. Severe orthopaedic or neurological (excluding Parkinson’s disease) pathology that will adversely affect gait&lt;br&gt;                6. Pain at the nVNS treatment site (e.g. dysaesthesia, neuralgia, cervicalgia)&lt;br&gt;                7. Previous use of nVNS stimulator device, including previous participation in nVNS research&lt;br&gt;                8. Women of child-bearing potential or who are pregnant&lt;br&gt;                9. Active participation in another interventional trial or exposure to an experimental drug or intervention&lt;br&gt;                10. Has a lesion (including lymphadenopathy), previous surgery (including carotid endarterectomy or vascular neck surgery) or abnormal anatomy at the treatment site (open wound, rash, infection, swelling, cut, sore, drug patch, surgical scar[s])&lt;br&gt;                11. Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of TIA or stroke), congestive heart failure (CHF), known severe coronary artery disease or prior myocardial infarction&lt;br&gt;                12. Abnormal baseline electrocardiogram (ECG) within the last year (e.g. second or third-degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation, clinically significant premature ventricular contraction)&lt;br&gt;                13. Uncontrolled high blood pressure (systolic &gt;160 mmHg, diastolic &gt;100 mmHg) after three measurements within 24 hours&lt;br&gt;                14. Has had a previous unilateral or bilateral vagotomy&lt;br&gt;                15. Has been implanted with metal cervical spine hardware, other metallic implants or implantable medical device (such as a deep brain stimulator, hearing aid implant, pacemaker, implantable cardioverter defibrillator, cranial aneurysm and/or cranial aneurysm clips, history of facial/orbital/metallic fragments, implanted electronic device, neurostimulator, valve replacements/stents, metallic implants/prostheses) near the stimulation site (such as stent, bone plate or bone screw)&lt;br&gt;                16. History of syncope or seizures (within the last 2 years)&lt;br&gt;                17. Patients with an active cancer or are in recent remission of cancer&lt;br&gt;                18. Clinically significant hypotension, bradycardia or tachycardia&lt;br&gt;                19. Known carotid atherosclerosis&lt;br&gt;                20. Insufficient comprehension of the English language&lt;br&gt;            
    </Exclusion_Criteria>
    <Condition>Parkinson’s disease &lt;br&gt;Nervous System Diseases &lt;br&gt;Parkinson disease
    </Condition>
    <Intervention>&lt;br&gt;                Participants will be asked to visit the research gait laboratory on three occasions separated by 12 weeks (for a total duration study duration of 24 weeks). All assessments will take place at the Clinical Ageing Research Unit (CARU), Newcastle Upon Tyne.&lt;br&gt;&lt;br&gt;                During the first study visit (baseline) participants will provide written informed consent. A screening interview will be completed to assess disease severity (MDS-UPDRS-III), concomitant medication and global cognition (Montreal Cognitive Assessment). A medical examination will be performed to confirm exclusion criteria. Following baseline assessments including motor, cognitive and autonomic functioning in addition to venous blood samples, participants will be allocated at random (using a balanced randomisation process) to one of two intervention arms to receive either active or sham nVNS or sham nVNS. Participants in the active group will receive non-invasive transcutaneous cervical Vagus Nerve Stimulation (nVNS) using the gammaCore® (electroCore, Basking Ridge, NJ, USA) handheld nVNS device. The device emits a low-voltage 5 kHz sine wave electrical signal burst that repeat once every 40 milliseconds (25 Hz frequency, maximum voltage: 24V, maximum intensity: 60 mA). Participants in the sham group will receive a device that is identical to the active nVNS device including appearance, user interface, weight, and audible feedback but delivers an electrical stimulus that causes a buzzing sensation to the skin but does not stimulate the vagus nerve. For the intervention, the two stimulation surfaces will be coated with conducting gel before being applied to the neck. The correct treatment site will be located, the stimulation surface placed on one side of the neck (left) and the stimulus a
    </Intervention>
    <Primary_outcome>&lt;br&gt;                1. Intervention safety measured by recording adverse events using self-reports and clinical judgment of the Chief investigator with interim phone calls at 4 and 8 weeks and at 12 weeks.&lt;br&gt;                2. Process indicators of the study: recruitment and randomisation rates defined by:&lt;br&gt;                2.1. Proportion of eligible patients who consent to participate in the trial at baseline&lt;br&gt;                2.2. Proportion of enrolled patients who successfully complete follow-up at 12 and 24 weeks&lt;br&gt;                3. Acceptability of study design including attendance rates, completion of nVNS, experience of intervention, retention and reasons for drop-outs, suitability of the intervention package, as assessed by questionnaires at 12 weeks&lt;br&gt;                4. Tolerability of multi-dose nVNS measured using self-reported compliance with interim phone calls at 4 and 8 weeks and at 12 weeks&lt;br&gt;            
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                1. Change in gait measured using an instrumented walkway and body-worn sensors at 12 and 24 weeks&lt;br&gt;                2. Change in macrostructural gait characteristics including volume, variability, pattern of walking bouts and steps measured using body-worn sensors and 7-day free-living monitoring at 12 and 24 weeks&lt;br&gt;                3. Change in attention and fluctuating attention measured using the simple reaction time (SRT), choice reaction time (CRT) and digit vigilance (DV) tasks (fluctuating attention is determined by the coefficient of variance of the three tasks) at 12 and 24 weeks&lt;br&gt;                4. Change in executive function measured using the One Touch Stockings of Cambridge (OTS) from the Cambridge Neuropsychological Test Automated Battery (CANTAB) computerised battery at 12 and 24 weeks&lt;br&gt;                5. Change in memory measured using the Paired Associates Learning (PAL) from CANTAB at 12 and 24 weeks&lt;br&gt;                6. The number of falls, fall rate and time to first fall measured prospectively using standardised falls diaries during the 12-week intervention period&lt;br&gt;                7. Change in autonomic function and heart-rate variability components measured using a cardiac monitor at 12 and 24 weeks&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>Nil known;Nil known;CPMS 49595, IRAS 292216
    </Secondary_ID>
    <Source_Support>Parkinson's UK; Grant Codes: G-1903, Dunhill Medical Trust; Grant Codes: RPGF1906\154
    </Source_Support>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>31/08/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>
</Trials_downloaded_from_ICTRP>